Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lighthouse Medical Communications US – An opportunity of a lifetime to be part of the Lucid Group magic

Our family at Lighthouse Medical Communications US are looking for talented individuals to join its team in hashtagManhattan. If you want to be part of something magical get in touch...

Lucid Learning and Development

Julieann Tate, Head of hashtagLearning and Development at Lucid Group, discusses the new programmes and tools she has been busy developing and rolling out throughout the organisation — Elevating employee...

Lucid Learning and Development

Julianne Tate, Head of Learning and Development at Lucid Group, discusses the new programmes and tools that she has been busy developing and rolling out throughout the Group — Elevating...

Lucid Group Announce Neil Flash as its New Chief Commercial Officer

With over 20 years’ healthcare communications experience, Neil Flash joins Lucid Group as its Chief Commercial Officer to help lead the organisation through another exciting period of growth.

My Journey into Medical Communications #LucidLife

In NetworkPharma's latest career guide for wannabe account managers, our very own Aveen Hamid discusses her journey into medical communications and the opportunity to work on programmes that transform patients’...

Lucid Group adds more magic to the mix with four new hires

Leading Edge, a Lucid Group company, injects new talent into its client services and medical writing teams. Miranda Harrison joins the team as its Client Operations Director. Miranda is a...

Lucid Group expands its presence in the north-west with six new hires

Healthcare 21, a Lucid Group company, continues to strengthen its editorial and medical writing team with six new additions to its Macclesfield office.Rosanna Farrell joins HealthCare 21 as a Senior...

There’s lots to celebrate as Lighthouse marks its five year anniversary

Based in Manhattan, Lighthouse Medical Communications US has grown significantly over the last five years, both in terms of team and client roster. Lisa Druce, Managing Partner comments, “Every year,...

Lucid Group bolsters its client services and medical writing team in APAC

HealthCare21, a Lucid Group company, has appointed two new team members in its Singapore office — Siew Wyn and Megan Giliam.Wyn joins the team as a Senior Account Manager and...

Lucid Group kick starts its 2020 Futures Academy

It’s a new year and the start of a new career for the six graduates starting on Lucid’s Futures Academy this week.This is Lucid’s fourth intake of graduates since the...